Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 16, 2024

Pazopanib vs Placebo in Patients With Metastatic Renal Cell Carcinoma With No Evidence of Disease After Metastasectomy

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
J. Clin. Oncol 2024 Mar 26;[EPub Ahead of Print], LJ Appleman, SE Kim, WB Harris, SK Pal, MR Pins, J Kolesar, N Agarwal, RA Parikh, DA Vaena, CW Ryan, M Hashmi, BA Costello, D Cella, JP Dutcher, RS DiPaola, NB Haas, LI Wagner, MA Carducci

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading